Cargando…

Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox

INTRODUCTION: Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022. The effectiveness of tecovirimat has been estimated against smallpox, which belongs to the same Orthopoxvirus genus as monkeypox. Thus, tecovirimat...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Tetsuya, Saito, Sho, Tsuzuki, Shinya, Ashida, Shinobu, Takakusaki, Mizue, Yoshikawa, Tomoki, Shimojima, Masayuki, Ebihara, Hideki, Ohmagari, Norio, Morioka, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394549/
https://www.ncbi.nlm.nih.gov/pubmed/37527886
http://dx.doi.org/10.1136/bmjopen-2022-069550
_version_ 1785083395887333376
author Suzuki, Tetsuya
Saito, Sho
Tsuzuki, Shinya
Ashida, Shinobu
Takakusaki, Mizue
Yoshikawa, Tomoki
Shimojima, Masayuki
Ebihara, Hideki
Ohmagari, Norio
Morioka, Shinichiro
author_facet Suzuki, Tetsuya
Saito, Sho
Tsuzuki, Shinya
Ashida, Shinobu
Takakusaki, Mizue
Yoshikawa, Tomoki
Shimojima, Masayuki
Ebihara, Hideki
Ohmagari, Norio
Morioka, Shinichiro
author_sort Suzuki, Tetsuya
collection PubMed
description INTRODUCTION: Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022. The effectiveness of tecovirimat has been estimated against smallpox, which belongs to the same Orthopoxvirus genus as monkeypox. Thus, tecovirimat is expected to be effective against monkeypox. This study aims to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox and monkeypox and to prepare a scheme for oral tecovirimat use in Japan. METHODS AND ANALYSIS: This nationwide, multicentre, non-randomised, open-label, double-arm study will involve viral examination of the blood, throat swabs, urine and skin lesions, performed periodically. Participants will freely decide whether to participate in an administered group (supportive treatment plus oral tecovirimat) or a non-administered group (only supportive treatment). Tecovirimat will be administered for 14 days. To ensure that financial problems do not preclude participation in the study, the research fund will cover the cost of tecovirimat and basic hospitalisation fees. The primary endpoint is the percentage of patients with negative PCR results (cycle threshold value ≥40) for skin lesion specimens at 14 days after inclusion in the study. Secondary endpoints include mortality at 14 and 30 days, viral load in each sample, duration of fever and adverse events. The sample size is estimated to be 50 patients with monkeypox or smallpox. ETHICS AND DISSEMINATION: Written informed consent will be obtained from all participants. This study was approved by the Certified Review Board of National Center for Global Health and Medicine and published in the Japan Registry of Clinical Trials. The results of this study will be published in peer-reviewed journals and/or in presentations at academic conferences. TRIAL REGISTRATION NUMBER: jRCTs031220169.
format Online
Article
Text
id pubmed-10394549
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103945492023-08-03 Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox Suzuki, Tetsuya Saito, Sho Tsuzuki, Shinya Ashida, Shinobu Takakusaki, Mizue Yoshikawa, Tomoki Shimojima, Masayuki Ebihara, Hideki Ohmagari, Norio Morioka, Shinichiro BMJ Open Infectious Diseases INTRODUCTION: Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022. The effectiveness of tecovirimat has been estimated against smallpox, which belongs to the same Orthopoxvirus genus as monkeypox. Thus, tecovirimat is expected to be effective against monkeypox. This study aims to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox and monkeypox and to prepare a scheme for oral tecovirimat use in Japan. METHODS AND ANALYSIS: This nationwide, multicentre, non-randomised, open-label, double-arm study will involve viral examination of the blood, throat swabs, urine and skin lesions, performed periodically. Participants will freely decide whether to participate in an administered group (supportive treatment plus oral tecovirimat) or a non-administered group (only supportive treatment). Tecovirimat will be administered for 14 days. To ensure that financial problems do not preclude participation in the study, the research fund will cover the cost of tecovirimat and basic hospitalisation fees. The primary endpoint is the percentage of patients with negative PCR results (cycle threshold value ≥40) for skin lesion specimens at 14 days after inclusion in the study. Secondary endpoints include mortality at 14 and 30 days, viral load in each sample, duration of fever and adverse events. The sample size is estimated to be 50 patients with monkeypox or smallpox. ETHICS AND DISSEMINATION: Written informed consent will be obtained from all participants. This study was approved by the Certified Review Board of National Center for Global Health and Medicine and published in the Japan Registry of Clinical Trials. The results of this study will be published in peer-reviewed journals and/or in presentations at academic conferences. TRIAL REGISTRATION NUMBER: jRCTs031220169. BMJ Publishing Group 2023-08-01 /pmc/articles/PMC10394549/ /pubmed/37527886 http://dx.doi.org/10.1136/bmjopen-2022-069550 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infectious Diseases
Suzuki, Tetsuya
Saito, Sho
Tsuzuki, Shinya
Ashida, Shinobu
Takakusaki, Mizue
Yoshikawa, Tomoki
Shimojima, Masayuki
Ebihara, Hideki
Ohmagari, Norio
Morioka, Shinichiro
Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
title Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
title_full Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
title_fullStr Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
title_full_unstemmed Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
title_short Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
title_sort protocol of tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394549/
https://www.ncbi.nlm.nih.gov/pubmed/37527886
http://dx.doi.org/10.1136/bmjopen-2022-069550
work_keys_str_mv AT suzukitetsuya protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT saitosho protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT tsuzukishinya protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT ashidashinobu protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT takakusakimizue protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT yoshikawatomoki protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT shimojimamasayuki protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT ebiharahideki protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT ohmagarinorio protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox
AT moriokashinichiro protocoloftecopoxstudyamulticentreopenlabeldoublearmtrialtoevaluatetheefficacyandsafetyoforaltecovirimattherapyforpatientswithsmallpoxormonkeypox